Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxaprozin
Drug ID BADD_D01635
Description Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Indications and Usage Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Marketing Status approved
ATC Code M01AE12
DrugBank ID DB00991
KEGG ID D00463
MeSH ID D000077431
PubChem ID 4614
TTD Drug ID D0M9DC
NDC Product Code 60760-092; 63629-8724; 17349-0008; 59762-6002; 0025-1381; 60760-203; 63629-1345; 69238-1120; 61919-178; 61919-673; 71335-0617; 71335-0902; 62135-176; 55111-013; 55111-170; 60760-382; 0185-0141; 55289-601
UNII MHJ80W9LRB
Synonyms Oxaprozin | 4,5-Diphenyl-2-oxazolepropionic Acid | 4,5 Diphenyl 2 oxazolepropionic Acid | Wy-21,743 | Wy 21,743 | Daypro | Rhoxal-oxaprozin | Rhoxal oxaprozin | Apo-Oxaprozin | Apo Oxaprozin | Danoprox | Dayrun
Chemical Information
Molecular Formula C18H15NO3
CAS Registry Number 21256-18-8
SMILES C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.0040.001040%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.0020.005302%
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Lethargy19.04.04.004; 08.01.01.008; 17.02.04.003--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.0030.004054%
Melaena07.12.02.004; 24.07.02.013--Not Available
Meningitis17.06.03.001; 11.01.03.001--
Menstrual disorder21.01.01.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.0010.008836%
Nephrotic syndrome20.05.01.002--
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.0060.003534%Not Available
Oesophagitis07.08.05.001--
Oliguria20.01.03.004--Not Available
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages